TCT 233: FANTOM II Study: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – Pooled Analysis From 3 Study Cohorts

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Abbott Vascular; REVA Medical; AstraZenca; BBraun</li></ul>